$4.71
0.00% yesterday
Nasdaq, Aug 18, 10:00 pm CET
ISIN
US74584P1030
Symbol
PULM

Pulmatrix Inc Stock price

$4.71
-1.50 24.15% 1M
-5.31 52.99% 6M
-2.27 32.52% YTD
+2.73 137.88% 1Y
+0.03 0.64% 3Y
-20.29 81.16% 5Y
-1,255.29 99.63% 10Y
-3,620.29 99.87% 20Y
Nasdaq, Closing price Mon, Aug 18 2025
+0.00 0.00%
ISIN
US74584P1030
Symbol
PULM
Industry

Key metrics

Basic
Market capitalization
$17.5m
Enterprise Value
$9.8m
Net debt
positive
Cash
$7.7m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
47.4 | 2.5
EV/Sales
26.5 | 1.4
EV/FCF
negative
P/B
2.5
Financial Health
Equity Ratio
90.0%
Return on Equity
-106.8%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$370.0k | $7.1m
EBITDA
- | -
EBIT
$-8.0m | $-19.4m
Net Income
$-7.9m | -
Free Cash Flow
$-8.0m
Growth (TTM | estimate)
Revenue
-96.8% | -8.5%
EBITDA
- | -
EBIT
8.0% | -171.5%
Net Income
26.8% | -
Free Cash Flow
40.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-2,169.1%
Net
-2,149.1% | -
Free Cash Flow
-2,172.4%
More
EPS
$-2.2
FCF per Share
-
Short interest
0.5%
Employees
2
Rev per Employee
$3.9m
Show more

Is Pulmatrix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Pulmatrix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pulmatrix Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pulmatrix Inc forecast:

Buy
86%
Hold
14%

Financial data from Pulmatrix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.37 0.37
97% 97%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.52 7.52
20% 20%
2,032%
- Research and Development Expense 0.85 0.85
94% 94%
230%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8 -8
8% 8%
-2,163%
Net Profit -7.93 -7.93
27% 27%
-2,143%

In millions USD.

Don't miss a Thing! We will send you all news about Pulmatrix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulmatrix Inc Stock News

Neutral
The Motley Fool
12 days ago
Pulmatrix (PULM) Q2 Revenue Falls 100%
Neutral
PRNewsWire
12 days ago
Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small or large molecule drugs to the lungs by inhalation FRAMINGHAM, Mass. , Aug, 6, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopha...
Neutral
PRNewsWire
3 months ago
Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ...
More Pulmatrix Inc News

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office United States
CEO Peter Ludlum
Employees 2
Founded 2015
Website www.pulmatrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today